Tequin taken out of production
Bristol-Myers Squibb will no longer make or market Tequin(gatifloxacin) but will not pull current supplies off the market.
Bristol-Myers Squibb will no longer make or market Tequin (gatifloxacin) but will not pull current supplies off the market. The company is returning its rights to Kyorin Pharmaceutical. In February, the FDA and BMS strengthened a warning against the use of Tequin by people with diabetes after reports of problems with high and low blood sugar associated with the drug. The watchdog group Public Citizen has petitioned the FDA to ban the drug, charging that it has caused deaths and hospitalizations.
To see more Hot off the Press news articles, click here click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
